The Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is spreading while the world has no approved vaccine or specific treatment for it. WHO states that none exists, and the DRC government said on 18 October that the virus had reached North Ubangi, an eighth affected province. The epidemic, which began in May 2026, has produced more than 9,000 confirmed cases. This report looks at the response and countermeasures: what is being tested, what is not yet available, and how far the outbreak has spread.
Bundibugyo virus outbreak: key takeaways
- Spread: seven provinces in agency data to 14 October; the government says North Ubangi is the eighth.
- Scale: ECDC reports 9,277 confirmed cases and 4,478 deaths in the DRC to 14 October.
- Countermeasures: WHO says no approved vaccine or specific treatment exists for Bundibugyo virus.
- Research: a WHO treatment trial began enrolling in July, and an Oxford-developed vaccine candidate has entered a phase 1 trial in Uganda.
- Response gap: 80.4% of contacts were being followed as of 4 October against an 85% target.
How far the Bundibugyo virus outbreak has spread
The ECDC’s page lists seven provinces with confirmed cases: Ituri, North Kivu, Haut-Uele, Tshopo, Bas-Uele, South Kivu and South Ubangi, covering 65 of 167 health zones. Ituri is the epicentre with 6,806 cases, followed by North Kivu with 1,991. Reports say the government has now named North Ubangi as an eighth province, with two cases reported, though surveillance summaries we reviewed do not yet include figures for it. North Kivu is reported to be imposing a one-week ban on entry from Ituri, limits on vehicle and motorbike passengers and a suspension of large gatherings.
What the Bundibugyo virus outbreak numbers show
By our own arithmetic from the ECDC figures, Ituri accounts for about 73% of the 9,277 confirmed cases and North Kivu for about 21%, so the two provinces hold roughly 95% of the total. The 65 affected health zones are about 39% of the 167 listed. Deaths of 4,478 against 9,277 cases give a crude ratio of about 48%, close to the 48.2% WHO reported on 6 October. These are our calculations from published figures, not official statistics, and a crude ratio can shift as outcomes of recent cases become known.
Why the Bundibugyo virus outbreak is hard to control without a vaccine
Vaccines licensed against Ebola target the Zaire species, and the WHO outbreak notice of 8 October 2026 says no approved vaccine or specific treatment exists for Bundibugyo virus. Without them, control depends on finding cases, isolating patients, tracing and following contacts, burying the dead safely and protecting health workers. WHO reported 80.4% of contacts followed as of 4 October, below its 85% target, and a crude case fatality ratio of 48.2% among confirmed cases. Those measures work but are labour intensive and hard to sustain across many provinces.
Treatments under study
WHO’s notice says a clinical trial to identify effective treatments began enrolling patients in July 2026. It gives no results, and we have seen none. Until a trial reports, clinicians are limited to supportive care. We make no claim that any specific product works against Bundibugyo virus, and readers should treat any such claim without trial evidence with caution.
Vaccine candidates in the Bundibugyo virus outbreak response
Researchers have begun a phase 1 trial in Uganda of an Oxford-developed candidate vaccine built on a ChAdOx platform, giving the first dose at a site in Masaka and planning to enrol 110 participants by November, according to reports. Separately, German researchers reported that the Ervebo vaccine, licensed for Zaire Ebola, triggers T-cell cross-reactivity against Bundibugyo, though it is unclear whether that protects infected people. A phase 1 trial tests safety and immune response in small numbers, so it is far from showing that a vaccine protects people in an outbreak.
Why trials are hard to run in an active outbreak
Trials of treatments and vaccines need participants who can be found early, followed up and tested reliably, and an outbreak spread over several provinces with insecurity and limited laboratory capacity makes that harder. Results also take time, because investigators need enough cases to compare outcomes between groups. That is general trial methodology, not a finding about this programme, and we have no information on enrolment totals for the WHO treatment trial.
Kenya, Uganda and the wider region
Kenya announced its first imported case on 6 October and reported an eighth case on 19 October, a 49-year-old hospital patient attendant, according to reports of the health director-general’s remarks. Uganda reported 20 cases before WHO declared its outbreak over on 25 August. The CDC’s situation summary rates the risk to the US public as low, and WHO rates the global risk as low while advising against travel or trade restrictions.
What we could not verify
We could not verify a death toll for North Ubangi, because official summaries do not yet include the province. Case totals differ by source and date: WHO had 8,728 cases to 6 October, ECDC had 9,277 to 14 October, and government figures cited on 18 and 19 October are at least 9,400.
Risks and caveats on the Bundibugyo virus outbreak
- Counts are moving daily and are revised.
- Vaccine candidates are at an early stage and unproven in this outbreak.
- Treatment trial results are not public.
- This is news reporting, not medical advice.
In our assessment, the Bundibugyo virus outbreak shows what happens when an outbreak outpaces its countermeasures, so the signals that matter are trial readouts, contact follow-up above the 85% target and the geographic footprint. See also Rwanda Battles Deadly Marburg Virus Outbreak: 66 Cases and Rising Fatalities Spark Urgent Response for an earlier filovirus outbreak. More in our industry insights coverage.
What to watch next on the Bundibugyo virus outbreak
- Results from the WHO treatment trial.
- Enrolment and early data from the Uganda vaccine trial.
- Official figures for North Ubangi.
- Contact follow-up rates against the 85% target.
Frequently asked questions
What is the Bundibugyo virus outbreak?
An Ebola disease outbreak in the DRC, caused by Bundibugyo virus, that began in May 2026.
Is there a vaccine or treatment?
WHO says none is approved. Trials of treatments and a vaccine candidate are under way.
How many provinces are affected?
Seven in agency data to 14 October, with the government naming North Ubangi as an eighth.
How we reported this: we relied on WHO, ECDC and CDC summaries and reports of government statements and trial launches. Last updated: 19 October 2026. This article is news reporting and not medical advice.
